Update: 12 Month Results for Anteris DurAVRTM Transcatheter Heart Valve (THV) Aortic Stenosis First in Human Study
Key Highlights:
1. The DurAVR™ Transcatheter Heart Valve (THV) First-in-Human Study met all performance endpoints with remarkable hemodynamic function sustained to 12 months.
2. DurAVR™ THV demonstrated an outstanding safety profile. All safety endpoints were met: No mortality (all causes), no disabling stroke, no life-threatening bleeding, and no myocardial infarction at 12 months.
3. These encouraging preliminary First-in-Human study results will be further validated in an FDA-approved Early Feasibility Study (EFS) in early 2023.
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)